REGENERATE: Obeticholic Acid Improves Liver Fibrosis in Expanded Analysis of Patients With NASH

November 8-12, 2019; Boston, Massachusetts
Obeticholic acid 10 mg and 25 mg improved liver fibrosis, steatohepatitis, and liver biochemistry in expanded ITT population that included patients with fibrosis stages 1-3.
Format: Microsoft PowerPoint (.ppt)
File Size: 169 KB
Released: November 12, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.

Juan Pablo Frias, MD, FACE Philip N. Newsome, PhD, FRCPE Released: January 28, 2020

Hear CCO faculty Rita Basu, MD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests

Rita Basu, MD Released: January 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue